ISPOR is spearheading the Initiative on US Value Assessment Frameworks with input and assistance from leading experts and key stakeholders in the health economics and outcomes research (HEOR) community.

The Initiative on US Value Assessment Frameworks was created to inform the shift towards a value-driven health care system by promoting the development and dissemination of high-quality, unbiased value assessment frameworks. Key aspects of the initiative include:

  1. Identify and discuss key methodological and process issues in defining and applying value frameworks to health care resource allocation issues;
  2. Convene a Special Task Force to collaborate on a white paper that reviews relevant perspectives and appropriate approaches and methods to support the definition and use of high-quality value frameworks; and
  3. Engage key stakeholders throughout the development of the white paper to help to frame the scope of work for this methodologically-oriented white paper and to review and comment on the Special Task Force’s work progress and products.

Phase I of the initiative focused on foundational work (i.e., conducting surveys and holding meetings with stakeholders and academic health economics and outcomes research experts; creating and reviewing a draft scope of work for Phase II; writing topical papers on issues in value assessment frameworks, etc.).

Phase II has focused on establishing a Special Task Force and producing a policy white paper on the appropriate definition and use of value frameworks, presenting the work, and discussing it with members and other stakeholders.

In the last few years, a number of value assessment frameworks have been developed as the US health care system has moved toward a value-driven approach that focuses on evaluating therapeutic options based on health outcomes, value to the patient, and effectiveness compared with other potential treatment options. The currently available frameworks, however, are widely diverse in their approaches, and this inconsistency can lead to variable evaluations of treatments. A need therefore exists for a robust discussion of relevant perspectives and appropriate approaches that (a) are transparent and methodologically sound and (b) involve the input of key stakeholders to guide the development of value assessment frameworks for health care decision making.

This initiative was led in Phase I by a founding Steering Committee which oversaw the engagement of an Expert Advisory Board and Stakeholder Advisory Panel. Phase II has been driven by the Special Task Force, co-chaired by Lou Garrison and Peter Neumann, with review and input from the Stakeholder Advisory Panel. The Expert Advisory Panel is composed primarily of health economists; a subset of the Expert Advisory Panel was chosen as the Special Task Force. The Stakeholder Advisory Panel includes patient representatives, industry leaders (drug, device, and diagnostics), payers, professional societies, and others. A list of the members of each group is included at the end of this FAQ.

The selection process was a two-staged approach. First, the Expert Advisory Board and the Stakeholder Advisory Panel were created during the second quarter of 2016. Given the need for timeliness in this effort, the Expert Advisory Board and Stakeholder Advisory Panel were selected by the Steering Committee, and include many distinguished scientists and contributors in this field. The Expert Advisory Board was consulted regarding methodological concerns in value assessment as preparation for drafting the Scope of Work for the Special Task Force. The Stakeholder Advisory Panel was surveyed regarding their concerns and perspectives on value frameworks; those results were also taken into account in drafting the Scope of Work.

The second stage of the selection process was to establish a Special Task Force in July 2016; its co-chairs are Lou Garrison and Peter Neumann. The Special Task Force includes 13 individuals who have demonstrated expertise in addressing the key concerns identified. The Special Task Force drafted their Scope of Work in early August, and that Scope of Work was distributed to the Expert Advisory Board and Stakeholder Advisory Panel for comment.

The initiative published a set of topical issue papers and will publish its final white paper. A number of the topical issue papers were published as a themed issue of Value in Health, the official journal of ISPOR. The Call for Papers that was distributed for this special collection of papers can be found here. That Call for Papers resulted in 125 abstract submissions, of which 35 were invited to submit full papers of which, following peer review, 22 were published in the February 2017 themed issue.

The Special Task Force plans to publish the final white paper in Value in Health in late 2017 or early 2018.

A number of conference presentations have been made (see the “Contribute to the Initiative”).

The Initiative has already benefited from several opportunities for member input:

  • Members were invited to respond to the Value in Health Call for Papers in May/June 2016; 22 papers from this Call were published in Value in Health in February 2017.
  • The initiative was referenced at several points during the May 2016 ISPOR 21st Annual International Meeting in Washington, DC, USA and member comments were discussed at those sessions. A brief overview of the initiative was presented by ISPOR’s Chief Science Officer, Dr. Richard Willke, during his remarks in the 2nd plenary on Tuesday, May 24, 2016 at 8:30-10:30 AM.
  • The 6th Biennial Conference of the American Society of Health Economists (ASHEcon) featured two consecutive sessions on the initiative on Tuesday, June 14, 2016. Dr. Willke chaired a session from 8:30-10:00 AM entitled, “Health Economic Perspectives on Value Frameworks” . Dr. Jalpa Doshi chaired the following session at 10:15-11:45 AM entitled, “Stakeholder Perspectives: A Roundtable on Value Assessment”. Additional information on ASHEcon 2016 can be found here.
  • ISPOR held an open Stakeholder Meeting on the initiative on Friday, September 23, 2016 in Washington, DC. The open meeting reviewed the planned scope of work for the initiative. Additional information on this meeting can be found here. Documents from the meeting can be found here.
  • An Issue Panel session regarding this initiative was held at the ISPOR 19th Annual European Congress in Vienna, Austria on Tuesday, November 1, 2016. Those presentations can be found here. (see Vienna lssue Panel slides)
  • Members of the Stakeholder Advisory Panel and Expert Advisory Board were asked to comment on the initial draft white paper.
  • An Issue Panel and a Workshop were held at the ISPOR 22nd Annual International Conference, Boston, MA, USA on Monday, May 22, 2017. These sessions reviewed the recommendations and several sections of the white paper, with stakeholder panel participants and audience discussion. Those presentations can be found here (see Boston Issue Panel slides and Boston Workshop slides)

Upcoming opportunities for input include:

  • The revised white paper is posted for member comments; the comment period closes at midnight (US Eastern time) August 4, 2017. All ISPOR members have been notified by email of its availability for review.
  • A session on value frameworks that discusses the white paper will be held at the International Health Economic Association meeting, Boston MA, July 10, 2017.
  • A session on value frameworks that discusses the white paper will be held at the ISPOR 6th Latin America Conference in São Paulo, Brazil, September 15-17, 2017.
  • If you would like to send other comments about the initiative, please write to CSO@ispor.org.

While health technology assessment is indeed a global concern with a number of important country and regional approaches in use, the recent interest in and proliferation of diverse value assessment frameworks in the US has suggested that a US-specific guidance is appropriate given the mix of stakeholder interests here. However, international perspectives and findings will certainly be incorporated in these deliberations, and a subsequent phase of this project is expected to take a more global approach.

Initiative Participant List


Expert Advisory Board

Anirban Basu, PhD (University of Washington)
Josh Carlson, PhD (University of Washington)
Michael E. Chernew, PhD (Harvard University)
Patricia M. Danzon, PhD (The Wharton School, University of Pennsylvania)
Jalpa Doshi, PhD (University of Pennsylvania)
Michael Drummond, MCom, DPhil (University of York)
A. Mark Fendrick, MD (University of Michigan)
Lou Garrison, PhD (University of Washington)
Henry A. Glick, PhD (University of Pennsylvania)
Dana Goldman, PhD (University of Southern California)
Darius Lakdawalla, PhD (University of Southern California)
Bryan Luce, PhD, MBA (Evidera)
David Meltzer, MD, PhD (University of Chicago)
C. Daniel Mullins, PhD (University of Maryland)
Peter J. Neumann, ScD (Tufts University School of Medicine)
Mark V. Pauly, PhD (The Wharton School, University of Pennsylvania)
Charles E. Phelps, PhD (University of Rochester)
Scott D. Ramsey, MD, PhD (University of Washington)
Shelby D. Reed, PhD (Duke University)
Frank A. Sloan, PhD (Duke University)
Adrian Towse, MA, MPhil (Office of Health Economics)
Milton C. Weinstein, PhD (Harvard University)
Richard J. Willke, PhD (ISPOR)

Special Task Force

Lou Garrison, PhD (University of Washington) co-chair
Peter J. Neumann, ScD (Tufts University School of Medicine) co-chair
Anirban Basu, PhD (University of Washington)
Michael E. Chernew, PhD (Harvard University)
Patricia M. Danzon, PhD (The Wharton School, University of Pennsylvania)
Jalpa Doshi, PhD (University of Pennsylvania)
Michael Drummond, MCom, DPhil (University of York)
Darius Lakdawalla, PhD (University of Southern California)
Mark V. Pauly, PhD (The Wharton School, University of Pennsylvania)
Charles E. Phelps, PhD (University of Rochester)
Scott D. Ramsey, MD, PhD (University of Washington)
Adrian Towse, MA, MPhil (Office of Health Economics)
Milton C. Weinstein, PhD (Harvard University)
Richard J. Willke, PhD (ISPOR), ex-officio

Stakeholder Advisory Panel *

Eleanor Perfetto, PhD (National Health Council)
Sara Van Geertruyden, JD (Partnership to Improve Patient Care)
Catherine Davis (Familial Hypercholesterolemia Foundation)
Linda House, RN, BSN, MSM (Cancer Support Community)
Joanna Siegel, SM, ScD (PCORI)
Amy Miller, PhD (Personalized Medicine Coalition)
Susan Cantrell, RPh (Academy of Managed Care Pharmacy)
Emily Wilson (American Society for Radiation Oncology)
Christian Downs, MHA, JD (Association of Community Cancer Centers)
Robert Dubois, MD, PhD (National Pharmaceutical Council)
Newell McElwee, PharmD, MSPH (Merck)
Sachin Kamal-Bahl, PhD (Pfizer)
Matthew Rousculp, PhD (GlaxoSmithKline)
Jason Spangler, MD, MPH (Amgen)
Joseph DiCesare, MPH (Novartis)
Priti Jhingran, PhD (Bristol-Myers Squibb)
James Murray, PhD (Eli Lilly and Company)
Deidre Mladsi (RTI-HS)
Nneka Onwudiwe, PharmD, PhD, MBA (US FDA)
Susan Garfield, DrPH, MSc (Ernst & Young)
Richard Charter, MSc (Becton Dickinson)
Andrew Baker, MBA, MPA (Stryker)
J. Jaime Caro, MDCM (Evidera)
Mark Sculpher, PhD, MSc (University of York)
Daniel Malone, PhD, RPh (University of Arizona)
Andrew Briggs, DPhil, MSc (Memorial Sloan Kettering Cancer Center and University of Glasgow)
Maarten IJzerman, PhD, MSc (University of Twente)
Rochelle Henderson, PhD (Express Scripts)
John Watkins, PharmD, MPH (Premera Blue Cross)
Renee JG Arnold, PharmD, RPh (Quorum Consulting)
Don May (AdvaMed)
Robert Boer, PhD (Allergan)

Initiative Research Support

Simrun (Simi) Grewal (PhD Student, University of Washington)

* Those listed above responded to at least one survey or commented on the draft white paper; approximately 40 other stakeholders were also solicited for comment.